Thus, it is not surprising that the combination of trametinib and low‐dose Type I RAF inhibitor (dabrafenib) failed in Phase II trial (TraMel‐WT, NCT04059224) for advanced NRASQ61R/K/L melanoma [176]. The gene discussed is RAF1; the disease is melanoma.